



BC Centre for Disease Control  
Provincial Health Services Authority

Communicable Diseases and Immunization Service  
655 West 12th Avenue  
Vancouver, BC V5Z 4R4

Tel 604.707.2548  
Fax 604.707.2515  
[www.bccdc.ca](http://www.bccdc.ca)

**Date:** January 22, 2021

**Administrative Circular:** 2021:04

**ATTN:** Medical Health Officers and Branch Offices  
Public Health Nursing Administrators and Assistant Administrators  
Holders of Communicable Disease Control Manuals

**Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,  
Part 4 – Biological Products**

**Part 4 – Biological Products**

**COVID-19 Vaccines**

**COVID-19 Vaccine After Care Sheet**

- The After Care Sheet has been revised to indicate that the [BC COVID-19 Self-Assessment Tool](#) should be used if the vaccine recipient experiences any symptoms compatible with COVID-19 infection, including respiratory symptoms (runny nose, sore throat, shortness of breath, etc.) or any symptoms listed as vaccine side effects, with the exception of local injection site reactions. This will determine whether they need to get tested for COVID-19.

**Please remove the following pages:** 1-2 dated January 13, 2021  
**Please add the following pages:** 1-2 dated January 22, 2021

**Immune Globulins**

**Immune Globulin (Ig): GamaSTAN®**

- The product name has been revised from GamaSTAN® S/D to GamaSTAN®.
- Indications for post-exposure prophylaxis of hepatitis A contacts have been revised to include the following groups for whom hepatitis A vaccine and Ig should be provided:
  - susceptible individuals with chronic liver disease
  - immunocompromised individuals who may not fully respond to the vaccine
  - may be considered for susceptible persons aged ≥ 60 years who are household or close contacts of a case of hepatitis A
- Footnote A has been added, indicating to see the [Communicable Disease Control Manual, Chapter 1: Hepatitis A](#) for information regarding hepatitis A contact management, including exposures in daycare centres and institutional settings.

Page 1 of 3

- Indication for pre-exposure prophylaxis for hepatitis A has been removed. For information regarding the use of pre-exposure Ig for the purpose of travel, see the [Canadian Immunization Guide: Part 5 - Passive Immunization](#).
- The dosage for post-exposure prophylaxis of hepatitis A contacts has been revised to 0.1 mL/kg as per the GamaSTAN® product monograph.

**Please remove page numbers:** 1-3 dated April 2015  
**Please add new page numbers:** 1-3 dated January 2021

**Immune Globulin Preparations or Blood: Timing Intervals for Vaccines Containing Live Measles, Mumps, Rubella or Varicella Virus**

- The dose for immune globulin (Ig) for post-exposure prophylaxis for hepatitis A has been revised to 0.1 mL/kg.

**Please remove page numbers:** 1-2 dated January 2016  
**Please add new page numbers:** 1-2 dated January 2021

**Please also remove the Title Page and Table of Contents for Part 4 – Biological Products dated December 23, 2020, and replace with the enclosed updated Title Page and Table of Contents dated January 2021.**

**COVID-19 Immunization Program - Question and Answer Document for Health Care Professionals**

- Question # 28 of the Q&A has been updated to indicate that in the context of limited supply, to allow for the protection of a larger number of at-risk individuals, vaccination with a COVID-19 vaccine may be delayed for 3 months following a PCR-confirmed infection, as reinfections reported to date have been rare within the first three months following infection. The updated Q&A can be found on the [Immunization Clinical Resources](#) page and the [COVID-19 Vaccine – Resources for health professionals](#) page.

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: [stephanie.meier@bccdc.ca](mailto:stephanie.meier@bccdc.ca)).

Sincerely,



Monika Naus MD MHSc FRCPC FACPM  
Medical Director  
Communicable Diseases & Immunization Service  
BC Centre for Disease Control

pc:

Provincial Health Officer  
Dr. Bonnie Henry

Dr. Reka Gustafson  
Vice President, Public Health &  
Wellness, PHSA & Deputy Provincial  
Health Officer

Deputy Provincial Health Officer  
Dr. Martin Lavoie

BC Ministry of Health, Population &  
Public Health Division:

Brian Sagar  
Senior Director Communicable  
Disease, Population and Public Health  
Division

Bernard Achampong  
Executive Director,  
Public Health, Planning and Prevention,  
Population and Public Health Division